|European Pharma Summit|
Drug Design & Medicinal Chemistry
GPCR Targeted Screening
Kinase Inhibitors in Drug Discovery
We invite you to attend the 5th GPCR Targeted Screening Conference, which will take place on November 16-17, 2017 in Berlin, Germany. G protein-coupled receptors are the largest family of protein receptors and account for one of the largest classes for drug targets currently in the market. Continued breakthrough and insights into the structural biology of GPCRs have opened up greater potential of this target class to impact drug discovery and renewed interest in this field.
The landscape for drug discovery has changed drastically over the past few years: private and public partnerships are changing how research is being done, researchers are using 3D model systems in hopes of improving clinical outcomes, and emerging target classes are changing traditional conceptions of the drug discovery process. Leaders in the field will share about advances in topics such as GPCRs in diseases, approaches to GPCR signaling, and biased signaling. Join us as we discuss basic biology to translational research in the field of GPCRs and gather for dedicated networking sessions with colleagues from academia and industry.
- Opening Plenary: Chemical Biology for Target Identification and Validation
- GPCR Structure-Based Drug Discovery
- GPCR Signaling Pathways and Mechanisms
- GPCRs in Metabolism
- Screening Technologies for GPCRs
- Closing Plenary: Hot Topics in Drug Discovery for the Future
We hope to see you there!
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Christel Menet, Confo Therapeutics|
|Eugenia Gurevich, Vanderbilt University|
|Tom Salt, University College London|
|Aylin Hanyaloglu, Imperial College London|
|Suzie Chen, Rutgers University|
|Philip Reeves, University of Essex|
|Patricia McDonald, The Scripps Research Institute|
|Christoph Klenk, University of Zurich|
|Dmitry Veprintsev, Paul Scherrer Institute|
|Peter Chidiac, University of Western Ontario|
|Graeme Milligan, University of Glasgow|
|Ruben Abagyan, University of California, San Diego|
|John Allen, UTMB|
|Ralf Jockers, INSERM|
|Toon Laeremans, Confo Therapeutics|
|Javier González-Maeso, Virginia Commonwealth University School of Medicine|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.